Join
Live feed
·
PRReleasevia Quantisnow
Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

ByQuantisnow·Wall Street's wire, on your screen.
JAZZ· Jazz Pharmaceuticals plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JAZZ (Jazz Pharmaceuticals plc) and more on Quantisnow.